Incannex to Commercialise its Psychedelic Clinics Business in Collaborative Partnership with Leading Psychedelic Experts
March 16, 2023 08:51 ET
|
Incannex Healthcare
Highlights: Incannex plans to open multiple psychedelic-assisted psychotherapy clinics in Australia and overseas.First clinic will open in Melbourne in 2023, followed by rapid expansion based...
Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment
March 15, 2023 07:30 ET
|
Incannex Healthcare
Highlights: Interim analysis of study data to date indicates that there is a greater than 85% chance (>85%, alpha error probability 0.05) of the study showing a statistically significant benefit...
Incannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinical Trials and Potential Commercial Use
March 03, 2023 07:30 ET
|
Incannex Healthcare
Highlights: Incannex has engaged Catalent for the development and cGMP manufacture of Incannex’s own psilocybin drug product.The psilocybin is designed for use in Incannex’s ongoing...
Incannex Commences Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis
February 28, 2023 07:25 ET
|
Incannex Healthcare
Highlights: Incannex has commenced a Phase 2, Blinded, Placebo Controlled Clinical Trial to Determine the Safety and Effect on Pain and Function of IHL-675A in Patients with Rheumatoid...
Independent data review commences for Phase 2 trial of psilocybin-assisted psychotherapy for anxiety
January 18, 2023 08:00 ET
|
Incannex Healthcare
MELBOURNE, Australia, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing proprietary...
Incannex Expands Intellectual Property Position over IHL-42X
December 06, 2022 08:00 ET
|
Incannex Healthcare
SYDNEY, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical company developing proprietary medicinal...
Incannex Engages Eurofins to Manufacture ReneCann Therapeutic Topical Application for Immune Disordered Skin Diseases
November 29, 2022 08:00 ET
|
Incannex Healthcare
MELBOURNE, Australia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing...
Incannex Engages Eurofins to Manufacture Novel Addiction Treatments CannQuit-N and CannQuit-O
November 28, 2022 08:00 ET
|
Incannex Healthcare
MELBOURNE, Australia, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing...
Incannex Development Update for IHL-42X for Obstructive Sleep Apnoea (‘OSA’)
November 17, 2022 08:00 ET
|
Incannex Healthcare
Highlights: Incannex has engaged CMAX Clinical Research and Novotech CRO to undertake a bioavailability/bioequivalence (‘BA/BE’) study to assess the pharmacokinetics and tolerability of IHL-42X in...
Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement
October 28, 2022 08:00 ET
|
Incannex Healthcare
MELBOURNE, Australia, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is...